Lantheus Holdings, Inc. (NASDAQ:LNTH) Short Interest Down 18.3% in July

Lantheus Holdings, Inc. (NASDAQ:LNTH) was the recipient of a significant drop in short interest in July. As of July 31st, there was short interest totalling 3,740,000 shares, a drop of 18.3% from the July 15th total of 4,580,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 3.5 days.

Lantheus Price Performance

LNTH traded down $0.19 during trading on Friday, hitting $94.91. The company’s stock had a trading volume of 488,780 shares, compared to its average volume of 1,062,541. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 14.49 and a beta of 0.51. Lantheus has a twelve month low of $50.20 and a twelve month high of $126.89. The business’s fifty day simple moving average is $95.35 and its 200 day simple moving average is $76.27. The company has a current ratio of 4.68, a quick ratio of 4.55 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. During the same period in the previous year, the firm posted $1.40 EPS. Lantheus’s revenue was up 22.5% compared to the same quarter last year. On average, equities research analysts forecast that Lantheus will post 6.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. B. Riley raised their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. SVB Leerink upped their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Mizuho lifted their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

Insider Activity

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the transaction, the director now owns 454,923 shares in the company, valued at approximately $43,445,146.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,439 shares of company stock worth $6,432,198. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Several large investors have recently modified their holdings of LNTH. Silverberg Bernstein Capital Management LLC lifted its holdings in Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after buying an additional 100 shares in the last quarter. Moody National Bank Trust Division increased its holdings in Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after purchasing an additional 162 shares during the period. Shaker Investments LLC OH raised its position in Lantheus by 0.7% in the 1st quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock valued at $1,740,000 after purchasing an additional 182 shares in the last quarter. NBC Securities Inc. boosted its stake in shares of Lantheus by 28.4% in the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 191 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.